CEPI Appoints Former Assistant Secretary for Preparedness and Response as New US Director

Nicole Lurie

The Coalition for Epidemic Preparedness Innovations (CEPI) made a major change at the top last week, with the appointment of former Assistant Secretary for Preparedness and Response (ASPR), Dr Nicole Lurie, as Director of United States.

Lurie has already been guiding CEPI’s emergency response efforts since 2017, including its response to COVID-19. She will remain a strategic advisor to the CEO of CEPI while carrying out her new role and will continue to help the global partnership develop vaccines to stop future epidemics.

“CEPI has been at the forefront of the global response to COVID-19, making some of the first investments in January 2020 that launched the development of vaccines against COVID-19,” Lurie said. “CEPI has become an irreplaceable part of the global R&D ecosystem, not only for COVID, but to accelerate the development of vaccines against emerging infectious diseases that could become epidemics or even future pandemics. I look forward to helping CEPI leverage the progress made in responding to COVID-19 to transform the world’s ability to prepare for and respond to epidemic and pandemic infectious diseases and ultimately create a future wherein these pathogens no longer pose an existential threat to humanity.”

Prior to joining CEPI, Lurie served as the President’s Appointed ASPR for eight years with the US Department of Health and Human Services (HHS). While there, she helped lead national responses to H1N1 and other infectious disease outbreaks. She also chaired the Public Health Emergency Medical Countermeasures Enterprise, a government effort to develop medical countermeasures against pandemics and other emerging threats.

“I am delighted that Dr. Lurie has agreed to lead CEPI’s work in the United States,” said CEPI CEO Richard Hatchett. “She brings unparalleled experience and expertise in emergency preparedness and response that will be critical to achieving CEPI’s ambitious long-term plans to reduce vaccine development timelines to 100 days and significantly reduce , or even eliminate, the risk of epidemics and pandemics.

Comments are closed.